TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER

INSTITUTIONAL BIOSAFETY COMMITTEE (IBC)

MINUTES

Tuesday, 09/09/2025 1:02 PM Zoom

Confidential Medical Document: This meeting agenda is intended for the sole use of the intended recipient(s) and contains confidential and privileged information. Unauthorized review, disclosure or distribution is prohibited.

MEETING ATTENDANCE

Voting members present: Abraham Al-Ahmad, PhD, Sharilyn Almodovar, PhD, Israel Chapa, Xiaodong Cheng, MD, PhD, Velvetlee Finckbone, MS, RLAT, Shayla Ford, BS, RN, Petar Grozdanov, PhD, Armando Hernandez, Aveline Hewetson, PhD, Magdalena Karbowniczek, MD, PhD, Cassie Kruczek, PhD, Malaiyalam Mariappan, PhD, Samuel Obeng, PhD, Stephen R Perez, Jyotsna Sharma, PhD, Dana Marie Telesford, PhD

Voting members absent: Byron Lara, Albert Patton III, BS, Scott Trasti, DVM

Guests present: Brian Pellam (Safety Services) from TTUHSC

Administrative staff present: Zachary Clark, MSHA

Ex officio present: Karlie Kennon

OLD BUSINESS

Meeting Minutes for the August meeting were approved as written. The following members abstained as they were not present during the August meeting: Velvetlee Finckbone, MS, RLAT, Shayla Ford, BS, RN, Petar Grozdanov, PhD, Magdalena Karbowniczek, MD, PhD, Malaiyalam Mariappan, PhD, Stephen R Perez, Scott Trasti. DVM

INITIAL SUBMISSIONS

N/A

3-YEAR RENEWALS

IBC # 22005 Expires: 09/30/2026 Ref: 095453 BSL: 2 Risk Group: 2

Risk Group: 2

PI: Ulrich Bickel. MD

Title: Institutional Biosafety Committee Review Item: IBC Protocol 3-Year Renewal

Training: All required trainings have been completed.

NIH Guidelines: Not Applicable Outcome: Approved

IBC # 16013 Expires: 09/30/2026 Ref: 095411 BSL: 2

PI: Sharda Prakash Singh, PhD Title: Institutional Biosafety Committee

Review Item: Submission Correction for IBC Protocol 3-Year Renewal

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-4 Outcome: Approved IBC # 07013 Expires: 09/30/2025 Ref: 095442 BSL: 2 Risk Group: 2

PI: Sanjay Srivastava, PhD

Title: Development and Characterization of Anticancer Compounds Using In Vitro Cancer Models

Review Item: Submission Correction for IBC Protocol 3-Year Renewal

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-4

Outcome: pending modifications (Post-Meeting FCR)

Stipulations: 1. Please update how animal carcass/ waste will be disposed of (section 6.0) in BSOP

Chemicals 1 and any others that will be used in animals.

2. Will LPS (3.1) generate any type of hazard.

3. With the removal of Coronavirus (BSL 1 and 2 only), check section 19.0 of the application as

NO.

FULL COMMITTEE REVIEW AMENDMENTS

N/A

DESIGNATED MEMBER REVIEW

N/A

ANNUAL STATUS REPORTS

IBC # 08014 Expires: 09/30/2026 Ref: 095473 BSL: 2 Risk Group: 2

PI: Min H Kang, PharmD

Title: Institutional Biosafety Committee

Review Item: IBC Annual Status Report

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-3

Outcome: Approved Administratively

IBC # 11001 Expires: 09/30/2026 Ref: 095458 BSL: 2 Risk Group: 2

PI: Magdalena Karbowniczek, MD, PhD Title: Institutional Biosafety Committee

Review Item: IBC Annual Status Report

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-4, Section III-D-3 Outcome: Approved Administratively

IBC # 18004 Expires: 09/30/2026 Ref: 095484 BSL: 2 Risk Group: 2

PI: Sivaramakrishna Koganti, PhD Title: Institutional Biosafety Committee

Review Item: IBC Annual Status Report

Training: All required trainings have been completed.

NIH Guidelines: Not Applicable

Outcome: Approved Administratively

IBC # 23007 Expires: 09/30/2026 Ref: 095439 BSL: 2 Risk Group: 2

PI: Balakrishna Koneru, PhD

Title: Institutional Biosafety Committee

Review Item: IBC Annual Status Report

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-3

Outcome: Approved Administratively

IBC # 24004 Expires: 09/30/2026 Ref: 095462 BSL: 2 Risk Group: 2

PI: Malaiyalam Mariappan, PhD
Title: Institutional Biosafety Committee

Review Item: IBC Annual Status Report

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-3

Outcome: Approved Administratively

IBC # 05017. Expires: 09/30/2026 Ref: 095457 BSL: 2 Risk Group: 2

PI: Kendra P Rumbaugh, PhD
Title: Institutional Biosafety Committee

Review Item: IBC Annual Status Report

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-1

Outcome: Approved Administratively

IBC # 12010 Expires: 09/30/2026 Ref: 095487 BSL: 2 Risk Group: 2

PI: Laurence Michael Wood, PhD
Title: Institutional Biosafety Committee

Review Item: IBC Annual Status Report

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-4

Outcome: Approved Administratively

ADMINISTRATIVE AMENDMENTS

IBC # 22006 Expires: 01/31/2026 Ref: 095489 BSL: 2 Risk Group: 2

PI: MahmoudSalama Ahmed, PhD

Title: Design, synthesis, and validation of new chemical entities targeting diseases

Review Item: IBC Protocol Amendment Form

Training: All required trainings have been completed.

NIH Guidelines: Not Applicable

Outcome: personnel and other changes; Approved Administratively

IBC # 17004 Expires: 06/30/2026 Ref: 095474 BSL: 2 Risk Group: 2

PI: Ronald Hall, PharmD

Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: not applicable)

Review Item: IBC Protocol Amendment Form

Training: All required trainings have been completed.

NIH Guidelines: Not Applicable

Outcome: add personnel; Approved Administratively

IBC # 17004 Expires: 06/30/2026 Ref: 095464 BSL: 2 Risk Group: 2

PI: Ronald Hall, PharmD

Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: not applicable)

Review Item: IBC Protocol Amendment Form

Training: All required trainings have been completed.

NIH Guidelines: Not Applicable

Outcome: remove personnel; Approved Administratively

IBC # 11015 Expires: 04/30/2026 Ref: 095141 BSL: 2 Risk Group: 2

PI: George Henderson, PhD

Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: EXEMPT)

Review Item: IBC Protocol Amendment Form

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-3

Outcome: location and other changes; Approved Administratively

IBC # 23005 Expires: 07/31/2026 Ref: 095452 BSL: 2 Risk Group: 2

PI: Samuel Obeng, PhD

Title: In vitro pharmacological characterization of novel compounds targeting GPCRs

Review Item: IBC Protocol Amendment Form

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-1

Outcome: add personnel; Approved Administratively

IBC # 15012 Expires: 08/31/2026 Ref: 095440 BSL: 2 Risk Group: 2

PI: Samuel Prien, PhD Title: Ob/Gyn Clinical Labs

Review Item: IBC Protocol Amendment Form

Training: All required trainings have been completed.

NIH Guidelines: Not Applicable

Outcome: add personnel; Approved Administratively

IBC # 21008 Expires: 03/31/2026 Ref: 095467 BSL: 2 Risk Group: 2

PI: Jenny Wilkerson, PhD

Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: Exempt)

Review Item: IBC Protocol Amendment Form

Training: All required trainings have been completed.

NIH Guidelines: Section III-F

Outcome: personnel and location change; Approved Administratively

TERMINATIONS

N/A

WITHDRAWALS

N/A

BSO REPORTS

Lab Inspections for September.

ADJOURNMENT

1:37 PM

^{*} Individual(s) with conflict of interest stepped out during vote.